Battle Of The Blockbusters: Lipitor Vs. Crestor In Atherosclerosis Progression Study Begins
This article was originally published in The Pink Sheet Daily
Executive Summary
1,300-patient, two-year Cleveland Clinic trial measures rate of regression of coronary disease.
You may also be interested in...
AstraZeneca’s SATURN “Moon Shot” Pitting Crestor Against Lipitor Misses The Mark
Top-line results from AstraZeneca’s SATURN trial in atherosclerosis seem unlikely to prevent erosion of Crestor’s (rosuvastatin) market share once generic versions of Pfizer’s Lipitor (atorvastatin) enter the market in November.
AstraZeneca’s SATURN “Moon Shot” Pitting Crestor Against Lipitor Misses The Mark
Top-line results from AstraZeneca’s SATURN trial in atherosclerosis seem unlikely to prevent erosion of Crestor’s (rosuvastatin) market share once generic versions of Pfizer’s Lipitor (atorvastatin) enter the market in November.
AstraZeneca's SATURN "Moon Shot" Pitting Crestor Against Lipitor Misses The Mark
Analysts, however, say the data miss is not a huge setback for AstraZeneca.